Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma

Authors

Manali Kamdar, University of Colorado
Hongli Li, Fred Hutchinson Cancer Research Center
Robert W. Chen, City of Hope Graduate School of Biological Science
Lisa M. Rimsza, Mayo Clinic, Phoenix, AZ
Michael L. Leblanc, Fred Hutchinson Cancer Research Center
Timothy S. Fenske, Medical College of Wisconsin
Thomas C. Shea, University of North Carolina at Chapel Hill
Paul M. Barr, University of Rochester
Tycel J. Phillips, The University Of Michigan
John P. Leonard, Weill Cornell Medical College
Brad S. Kahl, Washington University School of Medicine in St. Louis
Jonathan W. Friedberg, University of Rochester
Sonali M. Smith, University of Chicago

Journal

Blood Advances

Publication Date

2019

Volume

3

Issue

20

First Page

3132

Last Page

3135

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2019000526.

Rights and Permissions

Manali Kamdar, Hongli Li, Robert W. Chen, Lisa M. Rimsza, Michael L. Leblanc, Timothy S. Fenske, Thomas C. Shea, Paul M. Barr, Tycel J. Phillips, John P. Leonard, Brad S. Kahl, Jonathan W. Friedberg, Sonali M. Smith; Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Adv 2019; 3 (20): 3132–3135. doi: https://doi.org/10.1182/bloodadvances.2019000526

Recommended Citation

Kamdar, Manali; Li, Hongli; Chen, Robert W.; Rimsza, Lisa M.; Leblanc, Michael L.; Fenske, Timothy S.; Shea, Thomas C.; Barr, Paul M.; Phillips, Tycel J.; Leonard, John P.; Kahl, Brad S.; Friedberg, Jonathan W.; and Smith, Sonali M., "Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma." Blood Advances. 3, 20. 3132 - 3135. (2019).
https://digitalcommons.wustl.edu/open_access_pubs/8332